Provided by Tiger Trade Technology Pte. Ltd.

MiNK Therapeutics, Inc.

12.20
+0.58004.99%
Post-market: 12.200.00000.00%19:30 EDT
Volume:11.78K
Turnover:139.64K
Market Cap:62.26M
PE:-5.09
High:12.20
Open:11.64
Low:11.22
Close:11.62
52wk High:16.98
52wk Low:8.48
Shares:5.10M
Float Shares:2.07M
Volume Ratio:1.15
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3970
EPS(LYR):-2.9257
ROE:-1238.98%
ROA:-129.34%
PB:-4.44
PE(LYR):-4.17

Loading ...

Mink Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Apr 01

Mink Therapeutics Q4 EPS USD -0.56

THOMSON REUTERS
·
Mar 31

MiNK Therapeutics Q4 EPS $(0.56) Beats $(0.82) Estimate

Benzinga Earnings
·
Mar 31

Press Release: MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

Dow Jones
·
Mar 31

MiNK Therapeutics Explores Strategic Partnerships and Trial Collaborations

TIPRANKS
·
Mar 28

BRIEF-Mink Therapeutics Says Co Discussing Potential Combination Trials & Strategic Minority Investments

Reuters
·
Mar 27

Mink Therapeutics clarifies talks on agenT-797 combination trials; says no binding arrangements disclosed

Reuters
·
Mar 27

Mink Therapeutics Inc - in Discussions for Potential Combination Trials and Strategic Minority Investments - SEC Filing

THOMSON REUTERS
·
Mar 27

Mink Therapeutics Inc expected to post a loss of 82 cents a share - Earnings Preview

Reuters
·
Mar 27

Mink Therapeutics files initial beneficial ownership statement for Principal Accounting Officer Austin Charette

Reuters
·
Mar 24

MiNK Therapeutics Appoints New Principal Financial and Accounting Officers

TIPRANKS
·
Mar 20

Mink Therapeutics Inc - Appoints Melissa Orilall as Principal Financial Officer Effective March 13, 2026 - SEC Filing

THOMSON REUTERS
·
Mar 20

Mink Therapeutics names Melissa Orilall principal financial officer and Austin Charette principal accounting officer

Reuters
·
Mar 20

Mink Therapeutics to Report Q4 and Full-Year 2025 Financial Results and Host Conference Call

Reuters
·
Mar 17

MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

GlobeNewswire
·
Mar 17

Mink Therapeutics Inc expected to post a loss of 82 cents a share - Earnings Preview

Reuters
·
Mar 13

MiNK Therapeutics Director Barbara Ryan Disposes of Common Shares

Reuters
·
Mar 12

3 Penny Stocks to Watch Now, 3/11/26

TIPRANKS
·
Mar 11

Why Is MiNK Therapeutics Stock Trading Lower On Wednesday?

Benzinga
·
Mar 11

Top Premarket Decliners

MT Newswires Live
·
Mar 11